Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Investing.com -- Structure Therapeutics Inc ADR (NASDAQ:GPCR) stock soared 28.8% in premarket trading Monday after the company announced positive topline data from its ACCESS clinical program for ...
Accounting automation allows accounting firms to offer real-time insights to clients by reducing the time spent on manual processes. It creates space for ...
Shenzhen, Zhenjiang, Xiamen and Nanchang – approached developing low-carbon policies over the course of almost a decade ...
Real-time security clearances are becoming increasingly common in manufacturing of advanced-node semiconductors, where data ...
A recent Bloomberg Intelligence study found that buyside European equity traders want lighter regulation, more retail flow ...
A Fast Shift Toward Smarter Presales In 2025. Presales move fast this year, and many traders now want early-stage crypto ...
As DPIIT pushes a new framework for AI training and creator compensation, tech giants warn the plan could reshape India’s ...
Industry feedback signals growing pushback against India’s plan to license all “legally accessed” content for AI training.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback